Surveillance for hepatocellular carcinoma in patients with primary biliary cholangitis: For all or just for some?
作者信息
Giannini Edoardo G, Pasta Andrea, Labanca Sara, Pieri Giulia, Marenco Simona, Plaz Torres Maria Corina
机构信息
Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
出版信息
JHEP Rep. 2025 Feb 19;7(6):101362. doi: 10.1016/j.jhepr.2025.101362. eCollection 2025 Jun.
Abstract
摘要
相似文献
1
Surveillance for hepatocellular carcinoma in patients with primary biliary cholangitis: For all or just for some?原发性胆汁性胆管炎患者肝细胞癌的监测：针对所有人还是仅部分人？
JHEP Rep. 2025 Feb 19;7(6):101362. doi: 10.1016/j.jhepr.2025.101362. eCollection 2025 Jun.
2
Hepatocellular carcinoma in primary sclerosing cholangitis and primary biliary cholangitis: a clinical and pathological study in an uncommon but emerging setting.原发性硬化性胆管炎和原发性胆汁性胆管炎中的肝细胞癌：一种不常见但正在出现的情况下的临床和病理研究。
Virchows Arch. 2021 Dec;479(6):1131-1143. doi: 10.1007/s00428-021-03183-6. Epub 2021 Aug 20.
3
Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer?肝硬化期原发性硬化性胆管炎患者有发生肝细胞癌的风险吗？
J Hepatol. 1997 Sep;27(3):512-6. doi: 10.1016/s0168-8278(97)80356-x.
4
Risk of hepato-pancreato-biliary cancer is increased by primary sclerosing cholangitis in patients with inflammatory bowel disease: A population-based cohort study.炎症性肠病患者中，原发性硬化性胆管炎会增加肝胰胆管癌的风险：一项基于人群的队列研究。
United European Gastroenterol J. 2022 Mar;10(2):212-224. doi: 10.1002/ueg2.12204. Epub 2022 Feb 2.
5
Hepatocellular Carcinoma in Primary Biliary Cholangitis.原发性胆汁性胆管炎相关肝细胞癌。
Clin Liver Dis. 2022 Nov;26(4):691-704. doi: 10.1016/j.cld.2022.06.011.
6
Hepatocellular carcinoma with fibrolamellar pattern in a patient with autoimmune cholangitis.自身免疫性胆管炎患者的纤维板层型肝细胞癌。
Mt Sinai J Med. 1999 Mar;66(2):109-12.
7
Reply to: "Surveillance for hepatocellular carcinoma in patients with primary biliary cholangitis: For all or just for some?".回复：“原发性胆汁性胆管炎患者肝细胞癌的监测：针对所有患者还是部分患者？”
JHEP Rep. 2025 Mar 12;7(6):101395. doi: 10.1016/j.jhepr.2025.101395. eCollection 2025 Jun.
8
Rates of decompensation, hepatocellular carcinoma and mortality in AMA-negative primary biliary cholangitis cirrhosis.AMA 阴性原发性胆汁性胆管炎肝硬化患者的失代偿、肝细胞癌和死亡率。
Liver Int. 2022 Feb;42(2):384-393. doi: 10.1111/liv.15079. Epub 2021 Oct 12.
9
Primary biliary cholangitis metachronously complicated with combined hepatocellular carcinoma-cholangiocellular carcinoma and hepatocellular carcinoma.原发性胆汁性胆管炎异时性合并肝细胞癌-胆管细胞癌和肝细胞癌。
World J Hepatol. 2017 Dec 28;9(36):1378-1384. doi: 10.4254/wjh.v9.i36.1378.
10
Overlap syndrome of autoimmune hepatitis and primary biliary cholangitis complicated with atypical hepatocellular carcinoma: a case report.自身免疫性肝炎和原发性胆汁性胆管炎重叠综合征合并非典型肝细胞癌：一例报告。
J Med Case Rep. 2023 Jul 25;17(1):328. doi: 10.1186/s13256-023-03932-y.
引用本文的文献
1
Reply to: "Surveillance for hepatocellular carcinoma in patients with primary biliary cholangitis: For all or just for some?".回复：“原发性胆汁性胆管炎患者肝细胞癌的监测：针对所有患者还是部分患者？”
JHEP Rep. 2025 Mar 12;7(6):101395. doi: 10.1016/j.jhepr.2025.101395. eCollection 2025 Jun.
本文引用的文献
1
Risk of hepatocellular carcinoma in Asian patients with primary biliary cholangitis: A nationwide and hospital cohort study.亚洲原发性胆汁性胆管炎患者肝细胞癌的风险：一项全国性和医院队列研究。
JHEP Rep. 2024 Nov 6;7(2):101251. doi: 10.1016/j.jhepr.2024.101251. eCollection 2025 Feb.
2
Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis.预测原发性胆汁性胆管炎对奥贝胆酸反应的评分系统的开发与验证
Clin Gastroenterol Hepatol. 2024 Oct;22(10):2062-2074.e11. doi: 10.1016/j.cgh.2024.05.008. Epub 2024 May 22.
3
Excellent outcome in patients with primary biliary cholangitis in Northwest Italy followed up for up to 30 years.意大利西北部原发性胆汁性胆管炎患者随访长达 30 年的极佳结果。
Eur J Gastroenterol Hepatol. 2023 Aug 1;35(8):899-906. doi: 10.1097/MEG.0000000000002582. Epub 2023 Jun 6.
4
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid.预测原发性胆汁性胆管炎肝硬化患者接受奥贝胆酸治疗后发生严重不良事件和无应答的因素。
Liver Int. 2022 Nov;42(11):2453-2465. doi: 10.1111/liv.15386. Epub 2022 Aug 23.
5
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma.原发性胆汁性胆管炎和肝细胞癌患者的特征和生存情况。
Dig Liver Dis. 2022 Sep;54(9):1215-1221. doi: 10.1016/j.dld.2022.03.002. Epub 2022 Mar 27.
6
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis.X 染色体对原发性胆汁性胆管炎遗传结构的贡献。
Gastroenterology. 2021 Jun;160(7):2483-2495.e26. doi: 10.1053/j.gastro.2021.02.061. Epub 2021 Mar 4.
7
Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis.原发性胆汁性胆管炎患者发生肝细胞癌的发病率：系统评价和荟萃分析。
Dig Dis Sci. 2021 Jul;66(7):2439-2451. doi: 10.1007/s10620-020-06498-7. Epub 2020 Aug 2.
8
Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis.可溶性CD163和甘露糖受体作为原发性胆汁性胆管炎患者肝病严重程度和预后的标志物。
Liver Int. 2020 Jun;40(6):1408-1414. doi: 10.1111/liv.14466. Epub 2020 Apr 24.
9
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.原发性胆汁性胆管炎患者对熊去氧胆酸应答的预处理预测：UDCA 应答评分的建立和验证。
Lancet Gastroenterol Hepatol. 2018 Sep;3(9):626-634. doi: 10.1016/S2468-1253(18)30163-8. Epub 2018 Jul 13.
10
Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it?肝癌的早期诊断监测：如何才能做得更好？
World J Gastroenterol. 2013 Dec 21;19(47):8808-21. doi: 10.3748/wjg.v19.i47.8808.
Zotero 插件